CIBINETIDE / ARA-290
Cibinetide, originally known as ARA-290, is an 11-amino-acid peptide engineered from erythropoietin biology to activate a tissue-protective repair pathway without stimulating red-blood-cell production. Small randomized human trials in sarcoidosis-associated small-fiber neuropathy and type 2 diabetes have produced intriguing symptom and nerve-fiber signals.
Cibinetide is designed to switch on the body’s tissue-protection and repair signaling without the blood-building effects of erythropoietin, making it especially interesting for nerve damage, neuropathic symptoms and inflammation.
Still investigational.
This is more than a mechanistic peptide story: randomized human studies exist. The evidence remains relatively small and disease-specific, and cibinetide is not an FDA-approved treatment.
Erythropoietin biology—without trying to make more red blood cells.
Cibinetide is an 11-amino-acid peptide derived from the three-dimensional structure of erythropoietin and designed to activate tissue-protective signaling rather than erythropoiesis.
The research describes this pathway as an “innate repair receptor” involved in cytoprotection, modulation of inflammation and tissue repair. That mechanism has made cibinetide especially interesting in conditions involving small nerve fibers and inflammatory injury.
This is not just an animal-model story.
A 2012 randomized double-blind pilot trial enrolled 22 people with sarcoidosis and symptoms of small-fiber neuropathy. Cibinetide improved the Small Fiber Neuropathy Screening List score versus placebo at four weeks. Pain measured by the Brief Pain Inventory improved in both groups rather than showing a clear drug-placebo separation.
A subsequent blinded placebo-controlled study reported improvement in neuropathic symptoms along with increased corneal nerve-fiber density and changes in sensory and functional measures. In a later Phase 2b trial of 64 subjects, the 4 mg group showed a statistically significant placebo-corrected increase in corneal nerve-fiber area; pain improved in all groups.
A second human population produced another signal.
A Phase 2 study in people with type 2 diabetes and painful neuropathy reported improvements in neuropathic symptoms and metabolic measures during and after a 28-day treatment period.
The investigators also reported a nerve-fiber signal: participants starting with reduced corneal nerve-fiber density showed an increase compared with placebo. The study was exploratory and relatively small, so these findings are better treated as evidence supporting further clinical development than as definitive efficacy.
What people are actually reporting.
Public discussion tends to extend the small-fiber-neuropathy research into broader questions about nerve irritation, recovery and inflammatory discomfort. These are discussion themes, not measured outcomes or verified treatment responses.
Reports rarely establish whether a participant has a confirmed diagnosis, what product was used, or whether symptoms changed independently of other interventions. The controlled sarcoidosis and diabetic-neuropathy studies should not be generalized to all nerve conditions.
The community is extending a neuropathy story into a broader repair story.
Interest around ARA-290 increasingly centers on nerve pain, nerve recovery, inflammation and tissue repair.
Unlike many emerging compounds, that interest has a recognizable clinical foundation: neuropathy was actually studied in humans. The stretch occurs when disease-specific findings are generalized to unrelated nerve injuries, musculoskeletal recovery or broad systemic “healing.”
One of the narrower gaps in the emerging-peptide world.
MODERATE
For small-fiber neuropathy, the gap is narrower than it is for many peptides in the Index because controlled human studies include symptoms and objective nerve-fiber measures. The gap widens considerably when cibinetide is positioned as a general treatment for nerve injury, pain, inflammation or recovery.
Community Protocol Signal.
In public discussions, cibinetide / ARA-290 is described primarily in the context of nerve discomfort, neuropathy and tissue-protection goals. Some posts discuss injection schedules or short experimental cycles, but these reports are not validated treatment regimens.
Clinical trial administration schedules are study-specific and should not be repurposed as self-treatment guidance. No FDA-approved dosing regimen exists for cibinetide, and community products may not match the investigated substance.
Evidence boundary: community protocols cannot establish an effective dose, treatment duration, safety profile or appropriate patient population. The profile reports these themes for research literacy, not as instructions.
Investigational—and not supported for 503A compounding.
Cibinetide is not an FDA-approved drug. FDA's Substance Registration System recognizes Cibinetide, ARA-290 and ARA290 as names for the same substance, but FDA explicitly notes that a UNII identifier does not imply regulatory review or approval.
FDA's 503A bulks-list materials place Cibinetide (ARA-290) in Category 3: substances nominated without adequate support for evaluation. That is a compounding-status classification, not an assessment that the published human research is invalid.
Primary evidence behind the profile.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| 2012 · PMID 23168581 | Randomized double-blind placebo-controlled pilot; n=22 | Improved SFN symptom score in sarcoidosis; exploratory safety data. | Small sample; pain endpoints did not all clearly separate from placebo. |
| 2013 · PMID 24136731 | Blinded placebo-controlled sarcoidosis study | Neuropathic symptom improvement plus corneal nerve-fiber and functional signals. | Does not establish efficacy across other neuropathies. |
| 2015 · PMID 25387363 | Phase 2 type 2 diabetes + painful neuropathy study | Neuropathic symptom, metabolic and corneal nerve-fiber signals. | Exploratory findings require larger confirmation. |
| 2017 · PMID 28475703 | Randomized Phase 2b; n=64 | 4 mg group increased corneal nerve-fiber area and regenerating skin nerve fibers. | Pain improved across groups; structural surrogate does not itself prove broad clinical benefit. |
| FDA · 503A Categories | Compounding regulatory classification | Lists Cibinetide (ARA-290) in Category 3. | Does not adjudicate the validity of individual clinical studies. |
Read deeper.
Put the repair signal in context.
Recovery
Compare human neuropathy evidence with the broader peptide recovery landscape.
BPC-157
Compare ARA-290's controlled human neuropathy evidence with a recovery peptide whose reputation is driven much more heavily by preclinical and community signal.
Community Pulse
Track emerging nerve-recovery and inflammation signals beyond the clinical literature.
Cibinetide / ARA-290: a clinical signal, not an established neuropathy treatment
What the published evidence supports—and what it does not.
This evidence check does not change the profile’s existing community-reporting content or constitute medical advice.